Eric Rose, CMO knows prospects. He is buying. We'll see more insiders buying soon. I've topped up with an intention to sell at $2/s. GLTAH
"Mesoblast intends to file the resubmission this quarter, potentially resulting in an approval for
Ryoncil® (remestemcel-L) in the second half of CY2024. "
Source: APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED MARCH 31, 2024
Ann: Appendix 3Y for Eric Rose, page-29
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
0.018(1.65%) |
Mkt cap ! $1.218B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.06 | $974.5K | 909.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 47449 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 102428 | 12 |
View Market Depth
| Last trade - 12.30pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |